CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN

CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN

LISTING REQUIREMENTS

Berkeley Heights, NJ April 11, 2019 CorMedix Inc. (NYSE American: CRMD),

a biopharmaceutical company focused on developing and

commercializing therapeutic products for the prevention and

treatment of infectious and inflammatory disease, today announced

that on Friday, April 5, 2019, the NYSE American notified CorMedix

that the company had regained compliance with the NYSE American

listing requirements because the company has resolved the continued

listing deficiency with respect to Section 1003(a)(i), Section

1003(a)(ii) and Section 1003(a)(iii) of the NYSE American Company

CorMedix Inc. is a biopharmaceutical company focused on developing

and commercializing therapeutic products for the prevention and

treatment of infectious and inflammatory diseases. The Company is

focused on developing its lead product Neutrolin , a novel,

non-antibiotic antimicrobial solution designed to prevent costly

and dangerous bloodstream infections associated with the use of

central venous catheters, currently in Phase 3 development for

patients undergoing chronic hemodialysis. Such infections cost the

U.S. healthcare system approximately $6 billion annually and

contribute significantly to increased morbidity and mortality.

Neutrolin has FDA Fast Track status and is designated as a

Qualified Infectious Disease Product, which provides the potential

for priority review of a marketing application by FDA and

allows for 5 additional years of QIDP market exclusivity in the

event of U.S. approval. Neutrolin is already marketed as a CE

Marked product in Europe and other territories. In parallel,

CorMedix is leveraging its taurolidine technology to develop a

pipeline of antimicrobial medical devices, with active programs in

surgical sutures and meshes, and topical hydrogels. The

company is also working with top-tier researchers to develop

taurolidine-based therapies for rare pediatric cancers. For

more information, visit: www.cormedix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995

that are subject to risks and uncertainties. All statements, other

than statements of historical facts, regarding management's

expectations, beliefs, goals, plans or CorMedix's prospects,

future financial position, financing plans, future revenues and

projected costs should be considered forward-looking. Readers are

cautioned that actual results may differ materially from

projections or estimates due to a variety of important factors,

including: the resources needed to terminate the Phase 3 trial and

the costs and time needed to submit a new drug application to the

FDA; the risks and uncertainties associated with CorMedix's

ability to manage its limited cash resources and the impact on

current, planned or future research, including the continued

development of Neutrolin and research for additional uses for

taurolidine; obtaining

additional financing to support CorMedix's research and

development and clinical activities and operations; risks related

to obtaining FDA approval of the new drug application for

Neutrolin; relying on preclinical results that may not be

indicative of success in clinical trials and might not be

replicated in any subsequent studies or trials; and the ability to

retain and hire necessary personnel to staff our operations

appropriately. These and other risks are described in greater

detail in CorMedix's filings with the SEC, copies of which

are available free of charge at the SEC's website at

www.sec.gov or upon request from CorMedix. CorMedix may not

actually achieve the goals or plans described in its

forward-looking statements, and investors should not place undue

reliance on these statements. CorMedix assumes no obligation and

does not intend to update these forward-looking statements, except